http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4084B1_04_FDA-Marqibo.pdf
Table 1 Past Approvals for Non-Hodgkin’s Lymphoma (Reviewer Table)
Drug Approval Date Indication
Vincristine July 10, 1963 In combination with other chemotherapeutic
agents in the treatment of
Non-Hodgkin’s lymphomas
Vinblastine November 25, 1965 For the treatment of Non-Hodgkin’s
lymphomashttp://en.wikipedia.org/wiki/Vincristine
Vincristine (brand name, Oncovin), also known as leurocristine, is a vinca alkaloid from the Catharanthus roseus (Madagascar periwinkle), formerly Vinca rosea and hence its name. It is a mitotic inhibitor, and is used in cancer chemotherapy.
Vincristine was approved by the United States Food and Drug Administration (FDA) in July 1963 as Oncovin. The drug was initially discovered by a team lead by Dr. J.G. Armstrong; it was then marketed by Eli Lilly and Company。